BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 233 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $442,500 | -44.9% | 62,500 | -35.1% | 0.01% | -53.3% |
| Q1 2023 | $803,142 | -76.0% | 96,300 | -67.0% | 0.02% | -71.2% |
| Q4 2022 | $3,347,568 | -8.8% | 291,600 | 0.0% | 0.05% | +4.0% |
| Q3 2022 | $3,672,000 | -56.4% | 291,600 | -63.4% | 0.05% | -56.9% |
| Q2 2022 | $8,419,000 | -36.5% | 795,700 | -2.4% | 0.12% | -27.0% |
| Q1 2022 | $13,251,000 | +110.4% | 815,000 | +79.3% | 0.16% | +123.9% |
| Q4 2021 | $6,298,000 | -50.7% | 454,500 | -48.9% | 0.07% | -51.4% |
| Q3 2021 | $12,769,000 | -55.4% | 888,600 | -50.9% | 0.15% | -61.0% |
| Q2 2021 | $28,634,000 | +716.2% | 1,810,800 | +424.9% | 0.37% | +392.1% |
| Q1 2021 | $3,508,000 | +175.6% | 345,000 | -6.4% | 0.08% | +76.7% |
| Q4 2019 | $1,273,000 | +1283.7% | 368,700 | +1411.1% | 0.04% | +760.0% |
| Q2 2019 | $92,000 | -54.7% | 24,400 | -2.4% | 0.01% | -54.5% |
| Q1 2019 | $203,000 | – | 25,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DG Capital Management, LLC | 1,186,726 | $4,076,000 | 2.45% |
| Sarissa Capital Management LP | 4,861,000 | $16,697,000 | 1.97% |
| Ghost Tree Capital, LLC | 1,950,000 | $6,698,000 | 1.94% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,525,857 | $8,676,000 | 1.14% |
| Eversept Partners, LP | 1,143,211 | $3,926,930 | 0.87% |
| DAFNA Capital Management LLC | 749,051 | $2,573,000 | 0.84% |
| KNOTT DAVID M | 397,361 | $1,365,000 | 0.80% |
| Parkman Healthcare Partners LLC | 800,740 | $2,751,000 | 0.73% |
| ACUTA CAPITAL PARTNERS, LLC | 660,000 | $2,267,000 | 0.62% |
| Formidable Asset Management, LLC | 578,200 | $1,949,000 | 0.57% |